CareFusion Receives Consensus Recommendation of “Buy” from Brokerages (NYSE:CFN)
CareFusion (NYSE:CFN) has been given a consensus rating of “Buy” by the eleven brokerages that are presently covering the stock, StockRatingsNetwork reports. Five research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $42.45.
CareFusion (NYSE:CFN) opened at 42.86 on Friday. CareFusion has a 52-week low of $35.01 and a 52-week high of $44.17. The stock has a 50-day moving average of $41.5 and a 200-day moving average of $40.41. The company has a market cap of $8.885 billion and a P/E ratio of 23.97.
CareFusion (NYSE:CFN) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by $0.02. The company had revenue of $968.00 million for the quarter, compared to the consensus estimate of $986.67 million. During the same quarter in the previous year, the company posted $0.59 earnings per share. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. Analysts expect that CareFusion will post $2.31 EPS for the current fiscal year.
In other CareFusion news, CFO James F. Hinrichs sold 21,506 shares of the company’s stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $44.07, for a total value of $947,769.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Topeka Capital Markets initiated coverage on shares of CareFusion in a research note on Thursday. They set a “hold” rating and a $44.00 price target on the stock. Separately, analysts at Raymond James raised their price target on shares of CareFusion from $48.00 to $50.00 in a research note on Monday, May 19th. They now have a “strong-buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of CareFusion in a research note on Wednesday, May 7th. They now have a $41.00 price target on the stock.
CareFusion Corporation (NYSE:CFN) is a global medical technology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.